Interleukin-2/interferon-α2a/13-retinoic acid-based chemoimmunotherapy in advanced renal cell carcinoma: results of a prospectively randomised trial of the German Cooperative Renal Carcinoma Chemoimmunotherapy Group (DGCIN)-Reference-Cited by-同舟云学术

Interleukin-2/interferon-α2a/13-retinoic acid-based chemoimmunotherapy in advanced renal cell carcinoma: results of a prospectively randomised trial of the German Cooperative Renal Carcinoma Chemoimmunotherapy Group (DGCIN)

Published:2006-08 Issue:4 Volume:95 Page:463-469
ISSN:0007-0920
Container-title:British Journal of Cancer
language:en
Short-container-title:Br J Cancer

Author:

Atzpodien J, ,Kirchner H,Rebmann U,Soder M,Gertenbach U,Siebels M,Roigas J,Raschke R,Salm S,Schwindl B,Müller S C,Hauser S,Leiber C,Huland E,Heinzer H,Siemer S,Metzner B,Heynemann H,Fornara P,Reitz M

Publisher

Springer Science and Business Media LLC

Subject

Cancer Research,Oncology

Link

http://www.nature.com/articles/6603271.pdf

Reference20 articles.

1. Aass N, De Mulder PHM, Mickisch GH, van Oosterom AT, van Poppel H, Fossa SD, de Prijck L, Sylvester TJ (2005) Randomized phase II/III trial of interferon alfa-2a with and without 13-cis-retinoic acid in patients with progressive metastastic renal cell carcinoma: The European Organisation for Research and Treatment of Cancer Genito-Urinary Tract Cancer Group (EORTC 30951). J Clin Oncol 23: 4172–4278

2. Atzpodien J, Kirchner H, Duensing S, Lopez Hanninen E, Franzke A, Buer J, Probst M, Anton P, Poliwoda H (1995) Biochemotherapy of advanced metastatic renal-cell carcinoma: results of the combination of interleukin-2, alpha-interferon, 5-fluorouracil, vinblastine, and 13-cis-retinoic acid. World J Urol 13: 174–177

3. Atzpodien J, Kirchner H, Illiger HJ, Metzner B, Ukena D, Schott H, Funke PJ, Gramatzki M, von Jürgenson S, Wandert T, Patzelt T, Reitz M (2001) IL-2 in combination with IFN-α and 5-FU vs tamoxifen in metastatic renal cell carcinoma: Long-term results of a controlled randomized clinical trial. Br J Cancer 85 (8): 1130–1136

4. Atzpodien J, Kirchner H, Jonas U, Bergmann L, Schott H, Heynemann H, Fornara P, Loening SA, Roigas J, Müller SC, Bodenstein H, Pomer S, Metzner B, Rebmann U, Oberneder R, Siebels TI, Wandert T, Patzelt T, Reitz M, DGCIN-Group (2004) Interleukin-2- and interferon-alpha2a-based immunochemotherapy in advanced renal cell carcinoma: a prospectively randomized trial of The German Cooperative Renal Carcinoma Chemoimmunotherapy Group (DGCIN). J Clin Oncol 22 (7): 1188–1194

5. Atzpodien J, Korfer A, Franks CR, Knuver-Hopf J, Lopez-Hanninen E, Fischer M, Mohr H, Dallmann I, Hadam M (1990) Home therapy with recombinant interleukin-2 and interferon-alpha 2b in advanced human malignancies. Lancet 335: 1509–1512

Cited by 33 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. First-line therapy for adults with advanced renal cell carcinoma: a systematic review and network meta-analysis;Cochrane Database of Systematic Reviews;2023-05-04

2. Adverse effects of combination immunotherapy in renal cancer, lung cancer, and melanoma;Onkologie;2022-02-22

3. Interleukin-2 and Interferon-α for Advanced Renal Cell Carcinoma: Patient Outcomes, Sexual Dimorphism of Responses, and Multimodal Treatment Approaches over a 30-Year Period;Urologia Internationalis;2022

4. Chemoimmunotherapy in Advanced Renal Cell Carcinoma: A Case Report of a Long-Term Survivor Adjunctly Treated with Viscum album Extracts;Complementary Medicine Research;2019

5. Nivolumab induced encephalopathy in a man with metastatic renal cell cancer: a case report;Journal of Medical Case Reports;2018-09-15